Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

Clinical Therapeutics

Volumn 31, Issue 6, 2009, Pages 1142-1157

  Comi, Giancarlo ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

clinically isolated syndrome; disability progression; disease activity; immunomodulatory treatment; interferon beta; multiple sclerosis; relapsing remitting

Indexed keywords

ANALGESIC AGENT; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; PREDNISONE;

BRAIN ATROPHY; CHILL; CLINICAL TRIAL; CLINICALLY ISOLATED SYNDROME; DEMYELINATING DISEASE; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; EARLY DIAGNOSIS; EARLY INTERVENTION; FLU LIKE SYNDROME; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE REACTION; LABORATORY TEST; LOW DRUG DOSE; MULTIPLE SCLEROSIS; MYALGIA; NERVE INJURY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; OPTIC NEURITIS; PATIENT COMPLIANCE; REVIEW; RISK REDUCTION; SYMPTOM; THERAPY DELAY;

ADULT; AXONS; EARLY DIAGNOSIS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68649128836     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.06.007     Document Type: Review

References (84)

1. National Multiple Sclerosis Society. About MS: Who gets MS?. http://www.nationalmssociety.org/site/PageServer?pagename=HOM_ABOUT_who_gets_ms Accessed July 5, 2007
2. Confavreux C., Vukusic S., Moreau T., and Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 343 (2000) 1430-1438
3. Lublin F.D., Reingold S.C., and the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 46 (1996) 907-911
4. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: A geographically based study. I. Clinical course and disability. Brain 112 (1989) 133-146
5. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 655-661
6. Paty D.W., Li D.K., and the UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43 (1993) 662-667
7. Jacobs L.D., Cookfair D.L., Rudick R.A., et al., the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis [published correction appears in Ann Neurol. 1996;40:480]. Ann Neurol. 39 (1996) 285-294
8. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [published correction appears in Lancet. 1999;353:678]. Lancet 352 (1998) 1498-1504
9. Johnson K.P., Brooks B.R., Cohen J.A., et al., the Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45 (1995) 1268-1276
10. Comi G., Filippi M., Wolinsky J.S., and the European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 49 (2001) 290-297
11. Goodin D.S., Frohman E.M., Garmany Jr. G.P., et al., the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines [published correction appears in Neurology. 2002;59:480]. Neurology 58 (2002) 169-178
12. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol. 50 (2001) 121-127
13. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 Revisions to the "McDonald Criteria". Ann Neurol. 58 (2005) 840-846
14. Kuhlmann T., Lingfeld G., Bitsch A., et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125 (2002) 2202-2212
15. De Stefano N., Narayanan S., Francis G.S., et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 58 (2001) 65-70
16. Compston A. McAlpine's Multiple Sclerosis. 4th ed. (2005), Churchill Livingstone Elsevier, Philadelphia, Pa
17. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49 (1997) 1404-1413
18. Beck R.W., Trobe J.D., Moke P.S., et al., the Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 121 (2003) 944-949
19. Jacobs L.D., Beck R.W., Simon J.H., et al., the CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demy-elinating event in multiple sclerosis. N Engl J Med. 343 (2000) 898-904
20. Comi G., Filippi M., Barkhof F., et al., the Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet 357 (2001) 1576-1582
21. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67 (2006) 1242-1249
22. Galetta S.L. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study) [published correction appears in J Neuroophthalmol. 2002;22:67]. J Neuroophthalmol. 21 (2001) 292-295
23. Miller D., Barkhof F., Montalban X., et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 4 (2005) 281-288
24. Confavreux C., and Vukusic S. Natural history of multiple sclerosis: A unifying concept. Brain 129 (2006) 606-616
25. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 13 (1983) 227-231
26. Thorpe J.W., Kidd D., Kendall B.E., et al. Spinal cord MRI using multi-array coils and fast spin echo. I. Technical aspects and findings in healthy adults. Neurology 43 (1993) 2625-2631
27. Kidd D., Thorpe J.W., Thompson A.J., et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 43 (1993) 2632-2637
28. Lycklama à Nijeholt G.J., Uitdehaag B.M., Bergers E., et al. Spinal cord magnetic resonance imaging in suspected multiple sclerosis. Eur Radiol. 10 (2000) 368-376
29. Bot J.C., Barkhof F., Polman C.H., et al. Spinal cord abnormalities in recently diagnosed MS patients: Added value of spinal MRI examination. Neurology 62 (2004) 226-233
30. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120 (1997) 2059-2069
31. Uitdehaag B.M., Geurts J.J., Barkhof F., and Polman C.H. The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee. Neurology 63 (2004) 1140 author reply 1140
32. Roberts M.H., Martin J.P., McLellan D.L., et al. The prevalence of multiple sclerosis in the Southampton and South West Hampshire Health Authority. J Neurol Neurosurg Psychiatry 54 (1991) 55-59
33. Eriksson M., Andersen O., and Runmarker B. Long-term follow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis [published correction appears in Mult Scler. 2003;9:641]. Mult Scler. 9 (2003) 260-274
34. Bitsch A., Schuchardt J., Bunkowski S., et al. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 123 (2000) 1174-1183
35. Ferguson B., Matyszak M.K., Esiri M.M., and Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120 (1997) 393-399
36. Kornek B., Storch M.K., Weissert R., et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol. 157 (2000) 267-276
37. Lucchinetti C., Brück W., Parisi J., et al. Heterogeneity of multiple sclerosis lesions: Implications for pathogenesis of demyelination. Ann Neurol. 47 (2000) 707-717
38. Doinikow B. Evidence of transected axons. D Zeitschr Nervenheilkunde 26 (1915) 233-247
39. Trapp B.D., Peterson J., Ransohoff R.M., et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 338 (1998) 278-285
40. Lovas G., Szilágyi N., Majtényi K., et al. Axonal changes in chronic demy-elinated cervical spinal cord plaques. Brain 123 (2000) 308-317
41. Bjartmar C., Yin X., and Trapp B.D. Axonal pathology in myelin disorders. J Neurocytol. 28 (1999) 383-395
42. Ganter P., Prince C., and Esiri M.M. Spinal cord axonal loss in multiple sclerosis: A post-mortem study. Neuropathol Appl Neurobiol. 25 (1999) 459-467
43. Matthews P.M., Pioro E., Narayanan S., et al. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119 (1996) 715-722
44. Liu C., Edwards S., Gong Q., et al. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 66 (1999) 323-330
45. Rudick R.A., Fisher E., Lee J.C., et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53 (1999) 1698-1704
46. Filippi M., Rovaris M., Inglese M., et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, doubleblind, placebo-controlled trial. Lancet 364 (2004) 1489-1496
47. Brex P.A., Leary S.M., O'Riordan J.I., et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry 70 (2001) 544-547
48. Iannucci G., Tortorella C., Rovaris M., et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol. 21 (2000) 1034-1038
49. Fernando K.T., Tozer D.J., Miszkiel K.A., et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 128 (2005) 2911-2925
50. Rovaris M., Gambini A., Gallo A., et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 65 (2005) 1626-1630
51. Brex P.A., Jenkins R., Fox N.C., et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 54 (2000) 1689-1691
52. Paolillo A., Piattella M.C., Pantano P., et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: A monthly MRI study after triple-dose gadolinium-DTPA. J Neurol. 251 (2004) 432-439
53. Polman C., Kappos L., Freedman M.S., et al., for the BENEFIT investigators. Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. J Neurol. 255 (2008) 480-487
54. Barkhof F., Rocca M., Francis G., et al., the Early Treatment of Multiple Sclerosis Study Group. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Ann Neurol. 53 (2003) 718-724
55. Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol. 79 (2007) 423-447
56. Morrissey S.P., Miller D.H., Kendall B.E., et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain 116 (1993) 135-146
57. Beck R.W., Cleary P.A., Trobe J.D., et al., the Optic Neuritis Study Group. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med. 329 (1993) 1764-1769
58. O'Riordan J.I., Thompson A.J., Kingsley D.P., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121 (1998) 495-503
59. Brex P.A., Ciccarelli O., O'Riordan J.I., et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 346 (2002) 158-164
60. Filippi M., Horsfield M.A., Morrissey S.P., et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44 (1994) 635-641
61. O'Connor P., and CHAMPS. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: A post hoc analysis of data from CHAMPS. Clin Ther. 25 (2003) 2674-2865
62. Minneboo A., Barkhof F., Polman C.H., et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 61 (2004) 217-221
63. Tintoré M., Rovira A., Río J., et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 67 (2006) 968-972
64. Fisher E., Rudick R.A., Simon J.H., et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59 (2002) 1412-1420
65. Turner B., Lin X., Calmon G., et al. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler. 9 (2003) 21-27
66. Motamed M.R., Najimi N., and Fereshtehnejad S.M. The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clin Neurol Neurosurg. 109 (2007) 344-349
67. Pakdaman H., Sahraian M.A., Fallah A., et al. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurol Scand. 115 (2007) 429-431
68. Kinkel R.P., Kollman C., O'Connor P., et al., the CHAMPIONS Study Group. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66 (2006) 678-684
69. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: The ETOMS study 4-year results. Mult Scler. 8 Suppl 1 (2002) S23 Abstract
70. Kappos L., Freedman M.S., Polman C.H., et al., the BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 370 (2007) 389-397
71. Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. Neurology 53 (1999) 679-686
72. Kappos L., Polman C., Pozzilli C., et al., the European Study Group in Interferon beta-1b in Secondary-Progressive MS. Final analysis of the European multicenter trial on IFN beta-1b in secondary-progressive MS. Neurology 57 (2001) 1969-1975
73. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 56 (2001) 1496-1504
74. Panitch H., Miller A., Paty D., Weinshenker B., and the North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 63 (2004) 1788-1795
75. Rodegher M., Esposito F., Radaelli M., et al. Clinical and neuroradio-logical response to mitoxantrone in a large group of multiple sclerosis patients. J Neurol. 254 Suppl 3 (2007) O217 Abstract
76. Betaferon [summary of product characteristics]. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Betaferon/H-081-PI-en.pdf Accessed January 19, 2009
77. Synovate Healthcare, MS Global Monitor, Europen Survey, November 2004-February 2005.
78. Binquet C., Quantin C., Le Teuff G., et al. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis. Neuroepidemiology 27 (2006) 45-54
79. Tremlett H.L., and Oger J. Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology 61 (2003) 551-554
80. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multi-centre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352 (1998) 1491-1497
81. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128 (2005) 2705-2712
82. Serafini B., Rosicarelli B., Magliozzi R., et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14 (2004) 164-174
83. Lassmann H. Mechanisms of inflammation induced tissue injury in multiple sclerosis. J Neurol Sci. 274 (2008) 45-47
84. Rieckmann P. Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int MS J. 12 (2005) 42-51